EconPapers    
Economics at your fingertips  
 

PharmacoEconomics

1997 - 2020

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla ().

Access Statistics for this journal.
Track citations for all items by RSS feed
Is something missing from the series or not right? See the RePEc data check for the archive and series.


Volume 38, issue 2, 2020

Talkin’ About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices pp. 125-134 Downloads
Brendan Shaw and Jorge Mestre-Ferrandiz
One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit pp. 135-141 Downloads
Christopher McCabe, Mike Paulden, Isaac Awotwe, Andrew Sutton and Peter Hall
A Review of Health Economic Studies Comparing Traditional and Massively Parallel Sequencing Diagnostic Pathways for Suspected Genetic Disorders pp. 143-158 Downloads
Patrick Fahr, James Buchanan and Sarah Wordsworth
Measurement Properties of Commonly Used Generic Preference-Based Measures in East and South-East Asia: A Systematic Review pp. 159-170 Downloads
Xinyu Qian, Rachel Lee-Yin Tan, Ling-Hsiang Chuang and Nan Luo
Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment pp. 171-179 Downloads
David D. Kim, Gregory F. Guzauskas, Caroline S. Bennette, Anirban Basu, David L. Veenstra, Scott D. Ramsey and Josh J. Carlson
Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada pp. 181-192 Downloads
Feng Tian, Sherilyn K. D. Houle, Mhd. Wasem Alsabbagh and William W. L. Wong
How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness pp. 193-204 Downloads
Ben Kearns, John Stevens, Shijie Ren and Alan Brennan
Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models pp. 205-216 Downloads
Sabine E. Grimm, Xavier Pouwels, Bram L. T. Ramaekers, Ben Wijnen, Saskia Knies, Janneke Grutters and Manuela A. Joore
Transferability of Economic Evaluations of Treatments for Advanced Melanoma pp. 217-231 Downloads
Claire Gorry, Laura McCullagh and Michael Barry
Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis pp. 233-242 Downloads
T. Joseph Mattingly, Julia F. Slejko, Eberechukwu Onukwugha, Eleanor M. Perfetto, Shyamasundaran Kottilil and C. Daniel Mullins

Volume 38, issue 1, 2020

The New and Non-Transparent Cancer Drugs Fund pp. 1-4 Downloads
Eifiona M. Wood and Dyfrig A. Hughes
Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians pp. 5-24 Downloads
Alisa Likhitsup and Neehar D. Parikh
Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis pp. 25-37 Downloads
Alexander Konnopka and Hannah König
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA pp. 39-56 Downloads
Elizabeth Wehler, Natalie Boytsov, Claudia Nicolay, Oscar Herrera-Restrepo and Stacey Kowal
Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study pp. 57-68 Downloads
Dean A. Regier, David L. Veenstra, Anirban Basu and Josh J. Carlson
Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan pp. 69-84 Downloads
Luis Hernandez, Hiroyo Kuwabara, Anshul Shah, Kaoru Yamabe, Heather Burnett, Kyle Fahrbach, Maria Koufopoulou and Ryuichi Iwakiri
Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity pp. 85-95 Downloads
Susanne Schmitz, Tatjana T. Makovski, Roisin Adams, Marjan Akker, Saverio Stranges and Maurice P. Zeegers
Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes pp. 97-108 Downloads
Caitlin Smare, Khalid Lakhdari, Justin Doan, John Posnett and Sukhvinder Johal
The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation pp. 109-119 Downloads
Margrét V. Bjarnadóttir, David R. Anderson, Kislaya Prasad, Ritu Agarwal and D. Alan Nelson
Comment on: ‘NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence’ pp. 121-122 Downloads
Livio Garattini and Nicholas Freemantle
Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA pp. 123-123 Downloads
Elizabeth Wehler, Natalie Boytsov, Claudia Nicolay, Oscar Herrera-Restrepo and Stacey Kowal

Volume 37, issue 12, 2019

Could or Should We Use MCDA in the French HTA Process? pp. 1417-1419 Downloads
Salah Ghabri, Jean-Michel Josselin and Benoît Maux
Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review pp. 1421-1449 Downloads
Shuangshuang Fu, Chi-Fang Wu, Michael Wang and David R. Lairson
Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design pp. 1451-1468 Downloads
Daniel M. Sugrue, Thomas Ward, Sukhvir Rai, Phil McEwan and Heleen G. M. Haalen
The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments pp. 1469-1483 Downloads
Fernando Antonanzas, Carmelo Juárez-Castelló, Reyes Lorente and Roberto Rodríguez-Ibeas
Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort pp. 1485-1494 Downloads
Michael Laxy, Verena Maria Schöning, Christoph Kurz, Rolf Holle, Annette Peters, Christa Meisinger, Wolfgang Rathmann, Kristin Mühlenbruch and Katharina Kähm
Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II—An Updated Analysis of SEER-Medicare Data pp. 1495-1507 Downloads
Ya-Chen Tina Shih, Ying Xu, Chun-Ru Chien, Bumyang Kim, Yu Shen, Liang Li and Daniel M. Geynisman
Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn’s Disease pp. 1509-1523 Downloads
Heather Catt, Keith Bodger, Jamie J. Kirkham and Dyfrig A. Hughes
A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis pp. 1525-1536 Downloads
Sandjar Djalalov, Jaclyn Beca, Emmanuel M. Ewara and Jeffrey S. Hoch
Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies pp. 1537-1551 Downloads
Venediktos Kapetanakis, Thibaud Prawitz, Michael Schlichting, K. Jack Ishak, Hemant Phatak, Mairead Kearney, John W. Stevens, Agnes Benedict and Murtuza Bharmal
Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review pp. 1553-1553 Downloads
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li and Lizheng Shi

Volume 37, issue 11, 2019

Improving Transparency in Decision Models: Current Issues and Potential Solutions pp. 1303-1304 Downloads
Paul Tappenden and J. Jaime Caro
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood pp. 1305-1312 Downloads
Seamus Kent, Frauke Becker, Talitha Feenstra, An Tran-Duy, Iryna Schlackow, Michelle Tew, Ping Zhang, Wen Ye, Shi Lizheng, William Herman, Phil McEwan, Wendelin Schramm, Alastair Gray, Jose Leal, Mark Lamotte, Michael Willis, Andrew J Palmer and Philip Clarke
Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project pp. 1313-1320 Downloads
Jeroen P. Jansen, Devin Incerti and Mark T. Linthicum
Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States pp. 1321-1327 Downloads
Josh J. Carlson, Surrey M. Walton, Anirban Basu, Richard H. Chapman, Jonathan D. Campbell, R. Brett McQueen, Steven D. Pearson, Daniel R. Touchette, David Veenstra, Melanie D. Whittington and Daniel A. Ollendorf
A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling pp. 1329-1339 Downloads
Fernando Alarid-Escudero, Eline M. Krijkamp, Petros Pechlivanoglou, Hawre Jalal, Szu-Yu Zoe Kao, Alan Yang and Eva A. Enns
Cooking Up a Transparent Model Following a DICE Recipe pp. 1341-1347 Downloads
Jörgen Möller
Transparency in Health Economic Modeling: Options, Issues and Potential Solutions pp. 1349-1354 Downloads
Eric Q. Wu, Zheng-Yi Zhou, Jipan Xie, Cinzia Metallo and Praveen Thokala
Transparency in Decision Modelling: What, Why, Who and How? pp. 1355-1369 Downloads
Christopher Sampson, Renée Arnold, Stirling Bryan, Philip Clarke, Sean Ekins, Anthony Hatswell, Neil Hawkins, Sue Langham, Deborah Marshall, Mohsen Sadatsafavi, Will Sullivan, Edward C. F. Wilson and Tim Wrightson
Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics pp. 1371-1381 Downloads
Emma McManus, David Turner and Tracey Sach
NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence pp. 1383-1390 Downloads
Ash Bullement, Matthew Taylor, Sam Thomas McMordie, Errol Waters and Anthony James Hatswell
TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility pp. 1391-1408 Downloads
Nasuh C. Büyükkaramikli, Maureen P. M. H. Rutten- van Mölken, Johan L. Severens and Maiwenn Al
Publication of Decision Model Source Code: Attitudes of Health Economics Authors pp. 1409-1410 Downloads
Joanna Emerson, Rachel Bacon, Alma Kent, Peter J. Neumann and Joshua T. Cohen
Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics Authors pp. 1411-1411 Downloads
Joanna Emerson, Rachel Bacon, Alma Kent, Peter J. Neumann and Joshua T. Cohen

Volume 37, issue 10, 2019

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1195-1207 Downloads
Sabine E. Grimm, Debra Fayter, Bram L. T. Ramaekers, Svenja Petersohn, Rob Riemsma, Nigel Armstrong, Xavier Pouwels, Willem Witlox, Caro Noake, Gillian Worthy, Jos Kleijnen and Manuela A. Joore
Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1209-1217 Downloads
Matthew Walton, Sahar Sharif, Mark Simmonds, Lindsay Claxton and Robert Hodgson
Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review pp. 1219-1239 Downloads
Xiao Zang, Emanuel Krebs, Linwei Wang, Brandon D. L. Marshall, Reuben Granich, Bruce R. Schackman, Julio S. G. Montaner and Bohdan Nosyk
Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review pp. 1241-1260 Downloads
Dalia M. Dawoud, Alexander Haines, David Wonderling, Joanna Ashe, Jennifer Hill, Mihir Varia, Philip Dyer and Julian Bion
Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations pp. 1261-1276 Downloads
Jesse Elliott, Sasha Katwyk, Bláthnaid McCoy, Tammy Clifford, Beth K. Potter, Becky Skidmore, George A. Wells and Doug Coyle
Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand pp. 1277-1286 Downloads
Khachen Kongpakwattana, Zanfina Ademi, Thanaputt Chaiyasothi, Surakit Nathisuwan, Ella Zomer, Danny Liew and Nathorn Chaiyakunapruk
Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013 pp. 1287-1300 Downloads
Elizabeth D. Brouwer, Anirban Basu and Kai Yeung
Comment on: ‘The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study’ pp. 1301-1302 Downloads
Livio Garattini and Anna Padula

Volume 37, issue 9, 2019

Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1073-1080 Downloads
Shijie Ren, Hazel Squires, Emma Hock, Eva Kaltenthaler, Andrew Rawdin and Constantine Alifrangis
The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal pp. 1081-1091 Downloads
Edward Cox, Ros Wade, Mathilde Peron, Kristina Charlotte Dietz, Alison Eastwood, Stephen Palmer and Susan Griffin
Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions pp. 1093-1127 Downloads
Marina Treskova, Stefan M. Scholz and Alexander Kuhlmann
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations pp. 1129-1138 Downloads
Mario J. N. M. Ouwens, Pralay Mukhopadhyay, Yiduo Zhang, Min Huang, Nicholas Latimer and Andrew Briggs
Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample pp. 1139-1153 Downloads
Christine Mpundu-Kaambwa, Gang Chen, Elisabeth Huynh, Remo Russo and Julie Ratcliffe
Severity-Adjusted Probability of Being Cost Effective pp. 1155-1163 Downloads
Matthijs M. Versteegh, Isaac Corro Ramos, Nasuh C. Buyukkaramikli, Amir Ansaripour, Vivian T. Reckers-Droog and Werner B. F. Brouwer
Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe pp. 1165-1176 Downloads
Dominik Golicki, Michał Jakubczyk, Katarzyna Graczyk and Maciej Niewada
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States pp. 1177-1193 Downloads
Thomas E. Delea, Xinke Zhang, Jordan Amdahl, Diana Boyko, Franziska Dirnberger, Marco Campioni and Ze Cong

Volume 37, issue 8, 2019

Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma pp. 975-984 Downloads
Frederick W. Thielen, Nasuh C. Büyükkaramikli, Rob Riemsma, Debra Fayter, Nigel Armstrong, Ching-Yun Wei, Vanesa Huertas Carrera, Kate Misso, Gill Worthy, Jos Kleijnen and Isaac Corro Ramos
Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal pp. 985-993 Downloads
Becky Pennington, Shije Ren, Samantha Barton, Mariana Bacelar and Steven J. Edwards
Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review pp. 995-1010 Downloads
Nikolaos Maniadakis and Evgenia Konstantakopoulou
Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review pp. 1011-1027 Downloads
Stuart J. Wright, William G. Newman and Katherine Payne
The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective pp. 1029-1039 Downloads
Simon Frey, Tom Stargardt, Udo Schneider and Jonas Schreyögg
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck pp. 1041-1047 Downloads
Kim Cocks, Marta Contente, Sarah Simpson, Michael DeRosa, Fiona C. Taylor and James W. Shaw
Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions pp. 1049-1064 Downloads
Mutsa Gumbie, Bonny Parkinson, Henry Cutler, Natalie Gauld and Virginia Mumford
Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” pp. 1065-1067 Downloads
Katrine Wallace, Sandra Goble, Jeff Isaacson, Lara Maloney, Terri Cameron and Josh Bedel
Correction to: Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO) pp. 1069-1069 Downloads
Hui Shao, Vivian Fonseca, Charles Stoecker, Shuqian Liu and Lizheng Shi
Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia pp. 1071-1071 Downloads
Mark Bounthavong, Javed Butler, Chantal M. Dolan, Jeffrey D. Dunn, Kathryn A. Fisher, Nina Oestreicher, Bertram Pitt, Paul J. Hauptman and David L. Veenstra

Volume 37, issue 7, 2019

The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis pp. 871-877 Downloads
Eric Jutkowitz, Fernando Alarid-Escudero, Karen M. Kuntz and Hawre Jalal
Autologous Chondrocyte Implantation with Chondrosphere for Treating Articular Cartilage Defects in the Knee: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 879-886 Downloads
Xavier Armoiry, Ewen Cummins, Martin Connock, Andrew Metcalfe, Pamela Royle, Rhona Johnston, Jeremy Rodrigues, Norman Waugh and Hema Mistry
Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 887-894 Downloads
Bram L. T. Ramaekers, Rob Riemsma, Sabine Grimm, Debra Fayter, Sohan Deshpande, Nigel Armstrong, Willem Witlox, Xavier Pouwels, Steven Duffy, Gill Worthy, Jos Kleijnen and Manuela A. Joore
A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective pp. 895-919 Downloads
Steve Ryder, Kathleen Fox, Pratik Rane, Nigel Armstrong, Ching-Yun Wei, Sohan Deshpande, Lisa Stirk, Yi Qian and Jos Kleijnen
Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation pp. 921-929 Downloads
Hui Shao, Shuang Yang, Vivian Fonseca, Charles Stoecker and Lizheng Shi
Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients pp. 931-941 Downloads
Michelle Tew, Philip Clarke, Karin Thursky and Kim Dalziel
Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease pp. 943-952 Downloads
Yawen Jiang and Weiyi Ni
The Cancer Drugs Fund in Practice and Under the New Framework pp. 953-962 Downloads
Celia Sabry-Grant, Kinga Malottki and Alexander Diamantopoulos
Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” pp. 963-964 Downloads
R. Brett McQueen, Melanie D. Whittington, Rick H. Chapman, Varun M. Kumar and Jonathan D. Campbell
Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’ pp. 965-967 Downloads
Holly Guy, Lydia Walder and Mark Fisher
Correction to: Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities? pp. 969-969 Downloads
Paul Mark Mitchell, Sridhar Venkatapuram, Jeff Richardson, Angelo Iezzi and Joanna Coast
Correction to: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial pp. 971-971 Downloads
Baptiste Leurent, Manuel Gomes, Rita Faria, Stephen Morris, Richard Grieve and James R. Carpenter
Correction to: Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities pp. 973-973 Downloads
Edna Keeney, Dalia Dawoud and Sofia Dias

Volume 37, issue 6, 2019

Cost-Effectiveness Analysis in the Context of US Commercial Health Insurance pp. 743-744 Downloads
Bryan Dowd and John A. Nyman
Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges pp. 745-752 Downloads
David Thesmar, David Sraer, Lisa Pinheiro, Nick Dadson, Razvan Veliche and Paul Greenberg
Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 753-762 Downloads
Joanna Picot, Neelam Kalita, Wendy Gaisford, Petra Harris, Oluchukwu Onyimadu and Keith Cooper
Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 763-775 Downloads
Sarah Davis, Rachid Rafia, Christopher Carroll, Jean Hamilton and Munira Essat
Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review pp. 777-818 Downloads
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li and Lizheng Shi
Estimation of Cost for Endoscopic Screening for Esophageal Cancer in a High-Risk Population in Rural China: Results from a Population-Level Randomized Controlled Trial pp. 819-827 Downloads
Fuxiao Li, Xiang Li, Chuanhai Guo, Ruiping Xu, Fenglei Li, Yaqi Pan, Mengfei Liu, Zhen Liu, Chao Shi, Hui Wang, Minmin Wang, Hongrui Tian, Fangfang Liu, Ying Liu, Jingjing Li, Hong Cai, Li Yang, Zhonghu He and Yang Ke
A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis pp. 829-843 Downloads
Devin Incerti, Jeffrey R. Curtis, Jason Shafrin, Darius Lakdawalla and Jeroen P. Jansen
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden pp. 845-865 Downloads
Santiago Zuluaga-Sanchez, Megan Teynor, Christopher Knight, Robin Thompson, Thomas Lundqvist, Mats Ekelund, Annabelle Forsmark, Adrian D. Vickers and Andrew Lloyd
Correction to: The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study pp. 867-867 Downloads
José Leal, Stefania Manetti and James Buchanan
Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 869-869 Downloads
Hema Mistry, Chidozie Nduka, Martin Connock, Jill Colquitt, Theodoros Mantopoulos, Emma Loveman, Renata Walewska and James Mason

Volume 37, issue 5, 2019

Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes? pp. 627-630 Downloads
James F. O’Mahony
An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis pp. 631-643 Downloads
Matthew Franklin, James Lomas, Simon Walker and Tracey Young
Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal pp. 645-654 Downloads
Lindsay Claxton, Joanne O’Connor, Nerys Woolacott, Kath Wright and Robert Hodgson
Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 655-667 Downloads
Sabine E. Grimm, Nigel Armstrong, Bram L. T. Ramaekers, Xavier Pouwels, Shona Lang, Svenja Petersohn, Rob Riemsma, Gillian Worthy, Lisa Stirk, Janine Ross, Jos Kleijnen and Manuela A. Joore
Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review pp. 669-688 Downloads
Natalia Ruiz-Negrón, Jyothi Menon, Jordan B. King, Junjie Ma and Brandon K. Bellows
Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial pp. 689-699 Downloads
Aureliano Paolo Finch, Patricia van Velzen, Gerben ter Riet, Peter J. Sterk, Jan M. Prins and Judith E. Bosmans
Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States pp. 701-714 Downloads
Holly Guy, Vicki Laskier, Mark Fisher, W. Richey Neuman, Iwona Bucior, Steven Deitelzweig and Alexander T. Cohen
EQ-5D-5L Valuation for the Malaysian Population pp. 715-725 Downloads
Asrul Akmal Shafie, Annushiah Vasan Thakumar, Ching Jou Lim, Nan Luo, Kim Rand-Hendriksen and Faridah Aryani Md Yusof
Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology pp. 727-737 Downloads
Istvan M. Majer, Jean-Gabriel Castaigne, Stephen Palmer, Lucy DeCosta and Marco Campioni
Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal pp. 739-739 Downloads
Lindsay Claxton, Joanne O’Connor, Nerys Woolacott, Kath Wright and Robert Hodgson
Correction to: Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study pp. 741-741 Downloads
Matthew Franklin, Sarah Davis, Michelle Horspool, Wei Sun Kua and Steven Julious

Volume 37, issue 4, 2019

Advances in Methods and Novel Applications for Measuring Family Spillover Effects of Illness pp. 447-450 Downloads
Lisa A. Prosser and Eve Wittenberg
The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra pp. 451-456 Downloads
Werner Brouwer
Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution pp. 457-460 Downloads
Christopher McCabe
Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time pp. 461-473 Downloads
Scott D. Grosse, Jamison Pike, Rieza Soelaeman and J. Mick Tilford
Spillover Effects on Caregivers’ and Family Members’ Utility: A Systematic Review of the Literature pp. 475-499 Downloads
Eve Wittenberg, Lyndon P. James and Lisa A. Prosser
Using Discrete-Choice Experiment Methods to Estimate the Value of Informal Care: The Case of Children with Intellectual Disability pp. 501-511 Downloads
Sheena Arora, Stephen Goodall, Rosalie Viney and Stewart Einfeld
Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England pp. 513-530 Downloads
Sandy Tubeuf, Eirini-Christina Saloniki and David Cottrell
The Monetary Value of Informal Care: Obtaining Pure Time Valuations Using a Discrete Choice Experiment pp. 531-540 Downloads
Renske J. Hoefman, Job van Exel and Werner Brouwer
Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders pp. 541-551 Downloads
Tara A. Lavelle, Milton C. Weinstein, Joseph P. Newhouse, Kerim Munir, Karen A. Kuhlthau and Lisa A. Prosser
Economic Spillover Effects of Intensive Unpaid Caregiving pp. 553-562 Downloads
Josephine C. Jacobs, Courtney Van Houtven, Terri Tanielian and Rajeev Ramchand
Dementia Family Caregivers’ Willingness to Pay for an In-home Program to Reduce Behavioral Symptoms and Caregiver Stress pp. 563-572 Downloads
Eric Jutkowitz, Danny Scerpella, Laura T. Pizzi, Katherine Marx, Quincy Samus, Catherine Verrier Piersol and Laura N. Gitlin
Close-Person Spill-Overs in End-of-Life Care: Using Hierarchical Mapping to Identify Whose Outcomes to Include in Economic Evaluations pp. 573-583 Downloads
Alastair Canaway, Hareth Al-Janabi, Philip Kinghorn, Cara Bailey and Joanna Coast
An Examination of Downstream Effects of Bereavement on Healthcare Utilization for Surviving Spouses in a National Sample of Older Adults pp. 585-596 Downloads
Katherine A. Ornstein, Melissa M. Garrido, Albert L. Siu, Evan Bollens-Lund, Omari-Khalid Rahman and Amy S. Kelley
Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions pp. 597-608 Downloads
Pei-Jung Lin, Brittany D’Cruz, Ashley A. Leech, Peter J. Neumann, Myrlene Sanon Aigbogun, Dorothee Oberdhan and Tara A. Lavelle
Measuring Health Spillover Effects in Caregivers of Children with Autism Spectrum Disorder: A Comparison of the EQ-5D-3L and SF-6D pp. 609-620 Downloads
Clare C. Brown, J. Mick Tilford, Nalin Payakachat, D. Keith Williams, Karen A. Kuhlthau, Jeffrey M. Pyne, Renske J. Hoefman and Werner Brouwer
The Inclusion of Spillover Effects in Economic Evaluation: A Public Health Economics Perspective pp. 621-623 Downloads
Rhiannon Tudor Edwards
Correction to: Parental Health Spillover in Cost‑Effectiveness Analysis: Evidence from Self‑Harming Adolescents in England pp. 625-625 Downloads
Sandy Tubeuf, Eirini-Christina Saloniki and David Cottrell

Volume 37, issue 3, 2019

Determining Value in Health Technology Assessment: Stay the Course or Tack Away? pp. 293-299 Downloads
J. Jaime Caro, John Brazier, Jonathan Karnon, Peter Kolominsky-Rabas, Alistair J. McGuire, Erik Nord and Michael Schlander
Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review pp. 301-331 Downloads
Chun-Ru Chien, Daniel M. Geynisman, Bumyang Kim, Ying Xu and Ya-Chen Tina Shih
Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 333-343 Downloads
Paul Tappenden, Emma Simpson, Jean Hamilton, Daniel Pollard, Mark Clowes, Eva Kaltenthaler, David Meiklejohn and Nick Morley
Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 345-357 Downloads
Tosin Lambe, Rui Duarte, James Mahon, Sarah Nevitt, Janette Greenhalgh, Angela Boland, Sophie Beale, Eleanor Kotas, Joanne McEntee and Ian Pomeroy
Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review pp. 359-389 Downloads
Gian Luca Di Tanna, Anna Bychenkova, Frank O’Neill, Heidi S. Wirtz, Paul Miller, Briain Ó Hartaigh and Gary Globe
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States pp. 391-405 Downloads
Holly Guy, Lydia Walder and Mark Fisher
Measuring Public Preferences for Health Outcomes and Expenditures in a Context of Healthcare Resource Re-Allocation pp. 407-417 Downloads
Nicolas Krucien, Nathalie Pelletier-Fleury and Amiram Gafni
Opioid Use is Associated with Higher Severity-Adjusted Episode Costs in Patients with Conservatively Managed Degenerative Joint Disease of the Back and Neck pp. 419-433 Downloads
Brent A. Metfessel, Michelle D. Mentel, Amy Phanel, Mary Ann Dimartino, Mureen Allen and Samuel Ho
Cost Effectiveness of Inhaled Mannitol (Bronchitol®) in Patients with Cystic Fibrosis pp. 435-446 Downloads
Emma Warren, Kristen Morgan, Toby J. Toward, Matthias Schwenkglenks and Joanna Leadbetter

Volume 37, issue 2, 2019

Future Costs in Cost-Effectiveness Analyses: Past, Present, Future pp. 119-130 Downloads
Linda M. Vries, Pieter H. M. Baal and Werner Brouwer
Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal pp. 131-139 Downloads
Ros Wade, Alessandro Grosso, Emily South, Claire Rothery, Pedro Saramago, Laetitia Schmitt, Kath Wright and Stephen Palmer
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 141-153 Downloads
Nasuh C. Büyükkaramikli, Saskia Groot, Rob Riemsma, Debra Fayter, Nigel Armstrong, Piet Portegijs, Steven Duffy, Jos Kleijnen and Maiwenn J. Al
The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence pp. 155-167 Downloads
Richard Perry, George Braileanu, Thomas Palmer and Paul Stevens
Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review pp. 169-200 Downloads
Edward T. Chiyaka, Nghiem Van T., Lu Zhang, Abhishek Deshpande, Patricia Dolan Mullen and Phuc Le
Discrete Choice Experiments in Health Economics: Past, Present and Future pp. 201-226 Downloads
Vikas Soekhai, Esther W. Bekker-Grob, Alan R. Ellis and Caroline Vass
Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis pp. 227-238 Downloads
Tracey-Lea Laba, Helen K. Reddel, Nicholas J. Zwar, Guy B. Marks, Elizabeth Roughead, Anthony Flynn, Michele Goldman, Aine Heaney, Kirsty Lembke and Stephen Jan
Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States pp. 239-253 Downloads
Eytan Stein, Jipan Xie, Emilie Duchesneau, Subrata Bhattacharyya, Umakanth Vudumula, Briana Ndife, Gaetano Bonifacio, Annie Guerin, Nanxin Li and George Joseph
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data pp. 255-266 Downloads
Andrea Marcellusi, Raffaella Viti, Loreta A. Kondili, Stefano Rosato, Stefano Vella and Francesco Saverio Mennini
Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand pp. 267-278 Downloads
Bunchai Chongmelaxme, Pochamana Phisalprapa, Ratree Sawangjit, Piyameth Dilokthornsakul and Nathorn Chaiyakunapruk
Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding pp. 279-289 Downloads
Thananan Rattanachotphanit, Chulaporn Limwattananon, Onanong Waleekhachonloet, Phumtham Limwattananon and Kittisak Sawanyawisuth
Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand pp. 291-291 Downloads
Bunchai Chongmelaxme, Pochamana Phisalprapa, Ratree Manthaisong, Piyameth Dilokthornsakul and Nathorn Chaiyakunapruk

Volume 37, issue 1, 2019

Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution? pp. 1-6 Downloads
Salah Ghabri, Matt Stevenson, Jörgen Möller and J. Jaime Caro
Ibrutinib for Treating Waldenström’s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 7-18 Downloads
Paul Tappenden, Christopher Carroll, John Stevens, Emma Simpson, Praveen Thokala, Ruth Wong, Josh Wright and Rebecca Auer
Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 19-27 Downloads
Daniel Gallacher, Xavier Armoiry, Peter Auguste, Rachel Court, Theodoros Mantopoulos, Jacoby Patterson, Maria Santis, Joanne Cresswell and Hema Mistry
One Method, Many Methodological Choices: A Structured Review of Discrete-Choice Experiments for Health State Valuation pp. 29-43 Downloads
Brendan Mulhern, Richard Norman, Deborah J. Street and Rosalie Viney
Systematic Literature Review of the Economic Burden of Celiac Disease pp. 45-61 Downloads
Elizabeth S. Mearns, Aliki Taylor, Talia Boulanger, Kelly J. Craig, Michele Gerber, Daniel A. Leffler, Jennifer Drahos, David S. Sanders and Benjamin Lebwohl
Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany pp. 63-74 Downloads
Katharina Kähm, Michael Laxy, Udo Schneider and Rolf Holle
The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals pp. 75-84 Downloads
Becky Pennington, Monica Hernandez-Alava, Stephen Pudney and Allan Wailoo
Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off Study pp. 85-92 Downloads
Namita Joshi, Marja Hensen, Sachin Patel, Weiwei Xu, Kathy Lasch and Elly Stolk
Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool pp. 93-103 Downloads
Maria Gheorghe, Renske J. Hoefman, Matthijs M. Versteegh and Job Exel
Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer pp. 105-116 Downloads
Min Huang, M. Catherine Pietanza, Ayman Samkari, James Pellissier, Thomas Burke, Sheenu Chandwani, Fansen Kong and A. Simon Pickard
Correction to: The Future of Precision Medicine: Potential Impacts for Health Technology Assessment pp. 117-117 Downloads
James Love-Koh, Alison Peel, Juan Carlos Rejon-Parrilla, Kate Ennis, Rosemary Lovett, Andrea Manca, Anastasia Chalkidou, Hannah Wood and Matthew Taylor
Page updated 2020-01-27